Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2016

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2016


  • Products Id :- GMDHC0515TDB
  • |
  • Pages: 62
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2016', provides in depth analysis on Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted pipeline therapeutics.

The report provides comprehensive information on the Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)

- The report reviews Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics and enlists all their major and minor projects

- The report assesses Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Overview 8

Therapeutics Development 9

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Products under Development by Stage of Development 9

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Products under Development by Therapy Area 10

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Products under Development by Indication 11

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Products under Development by Companies 14

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 18

Assessment by Molecule Type 19

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Companies Involved in Therapeutics Development 20

Amgen Inc. 20

Array BioPharma Inc. 21

Astellas Pharma Inc. 22

CymaBay Therapeutics, Inc. 23

Daiichi Sankyo Company, Limited 24

F. Hoffmann-La Roche Ltd. 25

GlaxoSmithKline Plc 26

Hyundai Pharmaceutical Co., Ltd. 27

LG Life Science LTD. 28

Merck & Co., Inc. 29

Novartis AG 30

Sanwa Kagaku Kenkyusho Co., Ltd. 31

Taisho Pharmaceutical Holdings Co., Ltd. 32

Takeda Pharmaceutical Company Limited 33

Yuhan Corporation 34

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Drug Profiles 35

17-i - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

ARRY-981 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

AS-1669058 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

DA-1241 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

DS-8500 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

GSK-2041706 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

HD-0471042 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

HD-0471953 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

HOB-047 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

LC-34AD3 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

MBX-2982 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Small Molecule to Agonize GPR119 for Type 2 Diabetes - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Small Molecule to Agonize GPR119 for Type II Diabetes - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Small Molecule to Agonize GPR119 for Undisclosed Indication - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Small Molecule to Agonize GPR119 Receptor for Undisclosed Indication - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Small Molecules to Agonize GPR119 for Metabolic Disorders - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Small Molecules to Agonize GPR119 for Type II Diabetes - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Small Molecules to Agonize GPR119 Receptor for Type II Diabetes - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

YH-18420 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Dormant Projects 56

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Discontinued Products 58

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Featured News & Press Releases 59

Nov 05, 2009: Metabolex Closes $8.6 Million Financing Round 59

Nov 12, 2008: Metabolex Announces Positive Results From Phase 1a Clinical Trial Of MBX-2982 59

Mar 26, 2008: Metabolex, Inc. Initiates Phase 1 Trial Of MBX-2982 60

Appendix 61

Methodology 61

Coverage 61

Secondary Research 61

Primary Research 61

Expert Panel Validation 61

Contact Us 61

Disclaimer 62

List of Figures

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 19

List of Tables

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 19

Pipeline by Amgen Inc., H2 2016 20

Pipeline by Array BioPharma Inc., H2 2016 21

Pipeline by Astellas Pharma Inc., H2 2016 22

Pipeline by CymaBay Therapeutics, Inc., H2 2016 23

Pipeline by Daiichi Sankyo Company, Limited, H2 2016 24

Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 25

Pipeline by GlaxoSmithKline Plc, H2 2016 26

Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 27

Pipeline by LG Life Science LTD., H2 2016 28

Pipeline by Merck & Co., Inc., H2 2016 29

Pipeline by Novartis AG, H2 2016 30

Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2016 31

Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016 32

Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 33

Pipeline by Yuhan Corporation, H2 2016 34

Dormant Projects, H2 2016 56

Dormant Projects (Contd..1), H2 2016 57

Discontinued Products, H2 2016 58

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Amgen Inc.

Array BioPharma Inc.

Astellas Pharma Inc.

CymaBay Therapeutics, Inc.

Daiichi Sankyo Company, Limited

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

Hyundai Pharmaceutical Co., Ltd.

LG Life Science LTD.

Merck & Co., Inc.

Novartis AG

Sanwa Kagaku Kenkyusho Co., Ltd.

Taisho Pharmaceutical Holdings Co., Ltd.

Takeda Pharmaceutical Company Limited

Yuhan Corporation

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Therapeutic Products under Development, Key Players in Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Therapeutics, Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Pipeline Overview, Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Pipeline, Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Pipeline Assessment

select a license

Single User License
USD 3500 INR 224280
Site License
USD 7000 INR 448560
Corporate User License
USD 10500 INR 672840

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com